Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JT Licenses Antibody Drug Candidate to MedImmune
January 15, 2007
- PMDA Begins Drafting a New Review Policy
January 15, 2007
- Korosho to Conduct New Survey on Price Agreement Rates
January 15, 2007
- REGULATORY NEWS IN BRIEF ―１―
January 15, 2007
- REGULATORY NEWS IN BRIEF ―２―
January 15, 2007
- FY2007 Draft Budget Includes \68.8 Bil. to Promote Life Science R&D: MEXT
January 15, 2007
- Next Clinical Trial Promotion Plan to Be Announced By End of March
January 15, 2007
- UK DOH's Expert Group Issues Recommendations on First-in-man Trials of High-risk Agents
January 15, 2007
- BUSINESS NEWS IN BRIEF
January 8, 2007
- Hospitals to Demand that Insurers Pay Unpaid Copayments
January 8, 2007
- JPLA Seminae
January 8, 2007
- J&J Extends Its SOHO Day System to Include Employees with School Children
January 8, 2007
- UtoBrain Seminae
January 8, 2007
- No NHI Price Revision in FY2007: Chuikyo
January 8, 2007
- Gov't Approves 2.5% Budget Increase for Korosho
January 8, 2007
- Council to Begin Drafting Innovation 25 Strategy
January 8, 2007
- REGULATORY NEWS IN BRIEF
January 8, 2007
- STATISTICS
January 8, 2007
- 72% of Smokers Unaware of Insurance Coverage for Smoking Cessation: Novartis
January 8, 2007
- Mr Uchida of ABMJ Expresses High Expectations of Vaccine Study Group
January 8, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…